Paul Corn
Chair
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (47)
Treatment decisions in metastatic castration-resistant prostate cancer are mostly guided by clinical variables, but efforts to molecularly monitor the disease remain hampered by challenges in acquiring tumor tissue repeatedly. In this study, we simultaneously profiled the genome copy number and exome in longitudinal plasma circulating tumor DNA (ctDNA) acquired before, during, and upon progression to serial treatments with androgen signaling inhibitors and taxane chemotherapy from 60 patients with metastatic castration-resistant prostate cancer (2–10 samples per patient). The genomic data were used to delineate the clonal substructure and evolutionary dynamics of each patient, and an evolutionary dynamic index was developed to measure the longitudinal changes of the tumor subclones. Treatment with androgen signaling inhibitors resulted in greater subclonal selection and population structure changes than taxane treatment. The subclones that emerged in association with serial therapy resistance harbored recurrent aberrations in previously identified and new candidate genes, with particular enrichment in genes related to PI3K–AKT signaling. These findings indicate that the integration of detailed clinical and genomic data can provide a framework for future unbiased genomic applications for ctDNA in the clinic to enable precision medicine. Significance: Profiling of the genomic copy number changes and mutations in circulating tumor DNA collected longitudinally from prostate cancer patients receiving serial life-prolonging therapies elucidates evolutionary dynamics and identifies emerging resistant subclones.
Year:
2025
Year:
2025
Year:
2025
Therapeutic resistance in cancer significantly contributes to mortality, with many patients eventually experiencing recurrence after initial treatment responses. Recent studies have identified therapy-resistant large polyploid cancer cells in patient tissues, particularly in late-stage prostate cancer, linking them to advanced disease and relapse. Here, we analyzed bone marrow aspirates from 44 advanced prostate cancer patients and found the presence of circulating tumor cells with increased genomic content (CTC-IGC) was significantly associated with poorer progression-free survival. Single cell copy number profiling of CTC-IGC displayed clonal origins with typical CTCs, suggesting complete polyploidization. Induced polyploid cancer cells from PC3 and MDA-MB-231 cell lines treated with docetaxel or cisplatin were examined through single cell DNA sequencing, RNA sequencing, and protein immunofluorescence. Novel RNA and protein markers, including HOMER1, TNFRSF9, and LRP1, were identified as linked to chemotherapy resistance. These markers were also present in a subset of patient CTCs and are associated with recurrence in public gene expression data. This study highlights the prognostic significance of large polyploid tumor cells, their role in chemotherapy resistance, and the expression of markers tied to cancer relapse, offering new potential avenues for therapeutic development.
Year:
2025
Supplementary Table S13. Quantification of each protein-specific band normalized to vinculin (macrophage cells (RAW264.7) mono- or cocultured with RM-1-BM EV or SPOPmut models under treatment with OLA, Fig. 5E).
Year:
2025
Supplementary Fig. S19. Heatmaps of common differentially expressed genes in co-cultured and mono-cultured prostate cancer model tumor cells demonstrating significant (FDR
Year:
2025
Supplementary Fig. S21. Double immunofluorescence staining analysis of cleaved caspase 3 and PARP1 in C4-2b-empty vector and C4-2b-SPOPF133V xenograft tumors treated with talazoparib (TALA) or control vehicle
Year:
2025
Supplementary Table S3. Complete listing of antibodies used for immunoblotting (IB) and immunostaining analysis (Fig. 6C, 6D and Extended Data Fig. 5, 6). Vendor and catalog numbers are included in the list.
Year:
2025
Supplementary Table S2. Listing of protein features differentially expressed in Dox-inducible SPOPmut (F102C and F133V) C4-2b prostate cancer cells compared to C4-2b vector control shown in Fig. 2A upper panel
Year:
2025
Treatment decisions in metastatic castration-resistant prostate cancer are mostly guided by clinical variables, but efforts to molecularly monitor the disease remain hampered by challenges in acquiring tumor tissue repeatedly. In this study, we simultaneously profiled the genome copy number and exome in longitudinal plasma circulating tumor DNA (ctDNA) acquired before, during, and upon progression to serial treatments with androgen signaling inhibitors and taxane chemotherapy from 60 patients with metastatic castration-resistant prostate cancer (2–10 samples per patient). The genomic data were used to delineate the clonal substructure and evolutionary dynamics of each patient, and an evolutionary dynamic index was developed to measure the longitudinal changes of the tumor subclones. Treatment with androgen signaling inhibitors resulted in greater subclonal selection and population structure changes than taxane treatment. The subclones that emerged in association with serial therapy resistance harbored recurrent aberrations in previously identified and new candidate genes, with particular enrichment in genes related to PI3K–AKT signaling. These findings indicate that the integration of detailed clinical and genomic data can provide a framework for future unbiased genomic applications for ctDNA in the clinic to enable precision medicine. Significance: Profiling of the genomic copy number changes and mutations in circulating tumor DNA collected longitudinally from prostate cancer patients receiving serial life-prolonging therapies elucidates evolutionary dynamics and identifies emerging resistant subclones.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (31)
Ryan Park
Assistant Professor
The University of Texas MD Anderson Cancer Center
Chad Huff
Professor
The University of Texas MD Anderson Cancer Center
Timothy C. Thompson
Professor
The University of Texas MD Anderson Cancer Center
Johannes Fahrmann
Assistant Professor
The University of Texas MD Anderson Cancer Center
Theocharis Panaretakis
Associate Professor
Karolinska Institutet
Louis Pisters
Professor of Urology
The University of Texas MD Anderson Cancer Center
Nora M. Navone
Professor
The University of Texas MD Anderson Cancer Center
Christopher J. Logothetis
The University of Texas MD Anderson Cancer Center
Massimo Loda
Chair
Weill Cornell Medical College
Sue-Hwa Lin
Professor
The University of Texas MD Anderson Cancer Center
Andrew Futreal
Chair and Professor
The University of Texas MD Anderson Cancer Center
Jody Vykoukal
Group Leader
The University of Texas MD Anderson Cancer Center
Samir M. Hanash
The University of Texas MD Anderson Cancer Center
W. Robert Lee
Professor
Duke University
James P. Allison
Professor and Chair
The University of Texas MD Anderson Cancer Center
Susan Halabi
Duke University
Paul Viscuse
Assistant Professor
University of Virginia
Miao Zhang
Assistant Professor
The University of Texas MD Anderson Cancer Center
Mark Titus
Associate Professor
The University of Texas MD Anderson Cancer Center
Sreyashi Basu
The University of Texas MD Anderson Cancer Center
Ana Aparicio
Professor
The University of Texas MD Anderson Cancer Center
Eric Konnick
Associate Professor
University of Washington
Sumit Subudhi
Assistant Professor
The University of Texas MD Anderson Cancer Center
Nathaniel Wilson
Assistant Professor of Hematology and Medical Oncology
Winship Cancer Institute of Emory University
john Davis
Associate Professor
MD Anderson Cancer Center
Jeremiah Sanders
Assistant Professor and Senior Associate Consultant
Mayo Clinic
John Ward
Professor
MD Anderson Cancer Center
Mohamed Kamal
Research Scientist
University of Southern California
Timothy Yap
The University of Texas MD Anderson Cancer Center
Wenyi Wang
Professor
The University of Texas MD Anderson Cancer Center
Marites Melancon
Professor
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.